Cargando…

Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients

BACKGROUND: Inflammation is crucial to tumor progression. A traumatic event at a specific site in the brain activates the signaling molecules, which triggers inflammation as the initial response within the tumor and its surroundings. The educated immune cells and secreted proteins then initiate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhi, Puneet, Shrivastava, Richa, Garg, Nitin, Sorte, Sandeep K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546655/
https://www.ncbi.nlm.nih.gov/pubmed/34733616
http://dx.doi.org/10.5306/wjco.v12.i10.947
_version_ 1784590229811757056
author Gandhi, Puneet
Shrivastava, Richa
Garg, Nitin
Sorte, Sandeep K
author_facet Gandhi, Puneet
Shrivastava, Richa
Garg, Nitin
Sorte, Sandeep K
author_sort Gandhi, Puneet
collection PubMed
description BACKGROUND: Inflammation is crucial to tumor progression. A traumatic event at a specific site in the brain activates the signaling molecules, which triggers inflammation as the initial response within the tumor and its surroundings. The educated immune cells and secreted proteins then initiate the inflammatory cascade leading to persistent chronic inflammation. Therefore, estimation of the circulating inflammatory indicators kynurenine (KYN), interleukin-6 (IL-6), tissue-inhibitor of matrix-metalloproteinase-1 and human telomerase reverse transcriptase (hTERT) along with neutrophil-lymphocyte ratio (NLR) has prognostic value. AIM: To assess the utility of chosen inflammatory marker panel in estimating systemic inflammation. METHODS: The chosen markers were quantitatively evaluated in 90 naive, molecularly sub-typed plasma samples of glioma. A correlation between the markers and confounders was assessed to establish their prognostication power. Follow-up on the levels of the indicators was done 3-mo post-surgery. To establish the validity of circulating KYN, it was also screened qualitatively by dot-immune-assay and by immunofluorescence-immunohistochemistry in tumor tissues. RESULTS: Median values of circulating KYN, IL-6, hTERT, tissue-inhibitor of matrix-metalloproteinase-1 and NLR in isocitrate-dehydrogenase-mutant/wildtype and within the astrocytic sub-groups were estimated, which differed from controls, reaching statistical significance (P < 0.0001). All markers negatively correlated with mortality (P < 0.0001). Applying combination-statistics, the panel of KYN, IL-6, hTERT and NLR achieved higher sensitivity and specificity (> 90%) than stand-alone markers, to define survival. The inflammatory panel could discriminate between WHO grades, and isocitrate-dehydrogenase-mutant/wildtype and define differential survival between astrocytic isocitrate-dehydrogenase-mutant/wildtype. Therefore, its assessment for precise disease prognosis is indicated. Association of KYN with NLR, IL-6 and hTERT was significant. Cox-regression described KYN, IL-6, NLR, and hTERT as good prognostic markers, independent of confounders. Multivariate linear-regression analysis confirmed the association of KYN and hTERT with inflammation marker IL-6.There was a concomitant significant decrease in their levels in a 3-mo follow-up. CONCLUSION: The first evidence-based study of circulating-KYN in molecularly defined gliomas, wherein the tissue expression was found to be concomitant with plasma levels. A non-invasive model for assessing indicators of chronic systemic inflammation is proposed.
format Online
Article
Text
id pubmed-8546655
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-85466552021-11-02 Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients Gandhi, Puneet Shrivastava, Richa Garg, Nitin Sorte, Sandeep K World J Clin Oncol Observational Study BACKGROUND: Inflammation is crucial to tumor progression. A traumatic event at a specific site in the brain activates the signaling molecules, which triggers inflammation as the initial response within the tumor and its surroundings. The educated immune cells and secreted proteins then initiate the inflammatory cascade leading to persistent chronic inflammation. Therefore, estimation of the circulating inflammatory indicators kynurenine (KYN), interleukin-6 (IL-6), tissue-inhibitor of matrix-metalloproteinase-1 and human telomerase reverse transcriptase (hTERT) along with neutrophil-lymphocyte ratio (NLR) has prognostic value. AIM: To assess the utility of chosen inflammatory marker panel in estimating systemic inflammation. METHODS: The chosen markers were quantitatively evaluated in 90 naive, molecularly sub-typed plasma samples of glioma. A correlation between the markers and confounders was assessed to establish their prognostication power. Follow-up on the levels of the indicators was done 3-mo post-surgery. To establish the validity of circulating KYN, it was also screened qualitatively by dot-immune-assay and by immunofluorescence-immunohistochemistry in tumor tissues. RESULTS: Median values of circulating KYN, IL-6, hTERT, tissue-inhibitor of matrix-metalloproteinase-1 and NLR in isocitrate-dehydrogenase-mutant/wildtype and within the astrocytic sub-groups were estimated, which differed from controls, reaching statistical significance (P < 0.0001). All markers negatively correlated with mortality (P < 0.0001). Applying combination-statistics, the panel of KYN, IL-6, hTERT and NLR achieved higher sensitivity and specificity (> 90%) than stand-alone markers, to define survival. The inflammatory panel could discriminate between WHO grades, and isocitrate-dehydrogenase-mutant/wildtype and define differential survival between astrocytic isocitrate-dehydrogenase-mutant/wildtype. Therefore, its assessment for precise disease prognosis is indicated. Association of KYN with NLR, IL-6 and hTERT was significant. Cox-regression described KYN, IL-6, NLR, and hTERT as good prognostic markers, independent of confounders. Multivariate linear-regression analysis confirmed the association of KYN and hTERT with inflammation marker IL-6.There was a concomitant significant decrease in their levels in a 3-mo follow-up. CONCLUSION: The first evidence-based study of circulating-KYN in molecularly defined gliomas, wherein the tissue expression was found to be concomitant with plasma levels. A non-invasive model for assessing indicators of chronic systemic inflammation is proposed. Baishideng Publishing Group Inc 2021-10-24 2021-10-24 /pmc/articles/PMC8546655/ /pubmed/34733616 http://dx.doi.org/10.5306/wjco.v12.i10.947 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Observational Study
Gandhi, Puneet
Shrivastava, Richa
Garg, Nitin
Sorte, Sandeep K
Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients
title Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients
title_full Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients
title_fullStr Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients
title_full_unstemmed Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients
title_short Novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients
title_sort novel molecular panel for evaluating systemic inflammation and survival in therapy naïve glioma patients
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546655/
https://www.ncbi.nlm.nih.gov/pubmed/34733616
http://dx.doi.org/10.5306/wjco.v12.i10.947
work_keys_str_mv AT gandhipuneet novelmolecularpanelforevaluatingsystemicinflammationandsurvivalintherapynaivegliomapatients
AT shrivastavaricha novelmolecularpanelforevaluatingsystemicinflammationandsurvivalintherapynaivegliomapatients
AT gargnitin novelmolecularpanelforevaluatingsystemicinflammationandsurvivalintherapynaivegliomapatients
AT sortesandeepk novelmolecularpanelforevaluatingsystemicinflammationandsurvivalintherapynaivegliomapatients